On October 29, sodium iodide [¹³¹I] capsules independently developed and manufactured by CNNC HTA arrived at medical institutions in Macao. This marks the first time domestically produced sodium iodide [¹³¹I] capsules have been supplied to Macao, filling a longstanding gap in the availability of clinical services using sodium iodide [¹³¹I] and helping advance the development of nuclear medicine services in the region.
Addressing treatment gaps and strengthening Guangdong-Macao collaboration
Sodium iodide [¹³¹I] capsules are widely used in the diagnosis and treatment of thyroid diseases. Since the regular supply of radiopharmaceuticals from the Chinese mainland to Macao began, HTA has continued to expand its product portfolio for the Macao market.
Building on the establishment of a reliable cross-border supply of short-half-life radiopharmaceuticals, the introduction of sodium iodide [¹³¹I] capsules into clinical use in Macao will enable local medical institutions to provide more systematic radionuclide therapy. This will reduce the need for patients to travel across the border for treatment and help more people receive care for serious illnesses in Macao.

More than medication supply: better healthcare for all
Radiopharmaceuticals are unlike ordinary goods. They are time-critical medical products that can play a vital role in saving lives. A stable, compliant, and sustainable pharmaceutical supply channel between Guangdong and Macao goes beyond the delivery of medication: it also supports mutual recognition of standards in nuclear medicine diagnosis and treatment between the two regions.
Looking ahead, HTA will continue to uphold its mission of developing radiopharmaceuticals to benefit humanity. While further strengthening the security and reliability of its pharmaceutical supplies to Macao, the company will deepen exchanges and cooperation in nuclear medicine between the Chinese mainland, Hong Kong, and Macao. From clinical supply and technical collaboration to talent development and industrial integration, these efforts will help residents across the Guangdong-Hong Kong-Macao Greater Bay Area access more convenient and reliable nuclear medicine services, contributing to the Healthy China Initiative.